AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24915120 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-night rhythm
Number of subjects: 122
Study 24915120 — intervention group
Group type: COMPARATOR
Intervention: Standardized meal ingestion
Number of subjects: 122
Study 24915120 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 122
Study 24915261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (adjustable or nonadjustable banding, vertical banded gastroplasty, gastric bypass)
Number of subjects: 603
Study 24915261 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity and diabetes care (control group)
Number of subjects: 603
Study 24915261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 603
Study 24916038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells, administered intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks.
Number of subjects: 20
Study 24916038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells.
Number of subjects: 20
Study 24916144 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Cardiometry (EC)
Number of subjects: 374
Study 24916506 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FC (rituximab, fludarabine, and cyclophosphamide)
Number of subjects: 834
Study 24916506 — intervention group
Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 834
Study 24916507 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme-bound iron (hemin)
Number of subjects: 0
Study 24916507 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforced expression of erythroid Krüppel-like factor (EKLF)
Number of subjects: 0
Study 24916507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin
Number of subjects: 0
Study 24916507 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD patients
Number of subjects: 0
Study 24916507 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of iron overload
Number of subjects: 0
Study 24916770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 325 mg co-administered with gemcitabine 1,000 mg/m(2) (21-day dosing schedule)
Number of subjects: 46
Study 24916770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax doses escalated from 150 to 425 mg
Number of subjects: 46
Study 24916770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 325 mg with gemcitabine 1,000 mg/m(2)
Number of subjects: 46
Study 24916771 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-866 and cetuximab
Number of subjects: 11
Study 24916908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy preparation through TIPS trial
Number of subjects: 17
Study 24917216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 645
Study 24917216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 645
Study 24917420 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 30
Study 24917940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once daily
Number of subjects: 936
Study 24917940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study 24917966 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (H. pylori-positive patients)
Number of subjects: 589
Study 24917966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (H. pylori-positive patients)
Number of subjects: 589
Study 24917966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (H. pylori-negative controls)
Number of subjects: 589
Study 24917966 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. for 8 weeks (all patients)
Number of subjects: 589
Study 24918167 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment in patients with SLCO1B1 genotype rs4149056T>C
Number of subjects: 0
Study 24918167 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic recommendations based on SLCO1B1 genotype
Number of subjects: 0
Study 24918220 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 2233
Study 24918220 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 2233
Study 24918790 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg single-dose; 30 to 50 mg multiple-dose)
Number of subjects: 1154
Study 24918790 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 to 50 mg)
Number of subjects: 1154
Study 24918790 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 1154
Study 24918945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 61
Study 24918945 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn size, age, body fat percentage
Number of subjects: 61
Study 24918945 — intervention group
Group type: EXPERIMENTAL
Intervention: Time postburn, lean mass
Number of subjects: 61
Study 24918945 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 61
Study 24918982 — intervention group
Group type: EXPERIMENTAL
Intervention: TTD cohort
Number of subjects: 25
Study 24918982 — intervention group
Group type: EXPERIMENTAL
Intervention: TTD cohort (patients who died during follow-up)
Number of subjects: 25
Study 24919462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 8 mg/kg/week, administered intravenously for up to 12 cycles
Number of subjects: 46
Study 24919462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40)
Number of subjects: 46
Study 24919691 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected mothers' milk
Number of subjects: 82
Study 24919691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrations of DSLNT in 4-d milk samples
Number of subjects: 82
Study 24919854 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2835219
Number of subjects: 0
Study 24919854 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2835219 in combination with gemcitabine
Number of subjects: 0
Study 24919941 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFEspan service delivery model
Number of subjects: 0
Study 24920166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT) administered at baseline and annually thereafter
Number of subjects: 3845
Study 24920528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersensitive IBS patients
Number of subjects: 188
Study 24920528 — intervention group
Group type: COMPARATOR
Intervention: Normosensitive IBS patients
Number of subjects: 188
Study 24920586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib 0.24 to 2.23 mg/m(2) (days 1, 4, 8, 11; 21-day cycles)
Number of subjects: 60
Study 24920586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib 0.24 to 2.23 mg/m(2)
Number of subjects: 60
Study 24920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiotherapy and erlotinib
Number of subjects: 24
Study 24920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung dosimetric parameters
Number of subjects: 24
Study 24921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Action potentials (spiking)
Number of subjects: 2
Study 24921388 — intervention group
Group type: COMPARATOR
Intervention: Combined decoding of all LFPs
Number of subjects: 2
Study 24921388 — intervention group
Group type: EXPERIMENTAL
Intervention: LFPs (200-400 Hz)
Number of subjects: 2
Study 24921388 — intervention group
Group type: EXPERIMENTAL
Intervention: LFPs (0-7, 10-40, 50-65 Hz)
Number of subjects: 2
Study 24921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiking signals
Number of subjects: 2
Study 24921388 — intervention group
Group type: EXPERIMENTAL
Intervention: LFP signals
Number of subjects: 2
Study 24923295 — intervention group
Group type: EXPERIMENTAL
Intervention: AML+13 patients
Number of subjects: 34
Study 24923295 — intervention group
Group type: COMPARATOR
Intervention: ELN Intermediate-II patients
Number of subjects: 34
Study 24923356 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome
Number of subjects: 99
Study 24923356 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome older than 50 years
Number of subjects: 99
Study 24923356 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) levels in Turner syndrome on antihypertensive medication
Number of subjects: 99
Study 24923356 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of OPG levels with aortic diameter in Turner syndrome
Number of subjects: 99
Study 24923356 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of OPG levels with body surface area (BSA), weight, and plasma oestradiol levels in Turner syndrome
Number of subjects: 99
Study 24923356 — intervention group
Group type: COMPARATOR
Intervention: Osteoprotegerin (OPG) levels in controls
Number of subjects: 99
Study 24923792 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA users
Number of subjects: 54
Study 24923792 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA users with calcium intake ≥ 1 g/day
Number of subjects: 54
Study 24923792 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal contraceptive users
Number of subjects: 54
Study 24924750 — intervention group
Group type: EXPERIMENTAL
Intervention: Caproic acid (C6)
Number of subjects: 0
Study 24924750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauric acid (C12)
Number of subjects: 0
Study 24924750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid (C18:1)
Number of subjects: 0
Study 24924750 — intervention group
Group type: COMPARATOR
Intervention: Blank solutions with mineral oil
Number of subjects: 0
Study 24924750 — intervention group
Group type: EXPERIMENTAL
Intervention: NEFA emulsions
Number of subjects: 0
Study 24924798 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 617
Study 24924798 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 617
Study 24924798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open surgery
Number of subjects: 617
Study 24925211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine
Number of subjects: 10
Study 24925526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) 400 ng/min
Number of subjects: 33
Study 24925526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (0.4 µmol·min(-1)·l(-1))
Number of subjects: 33
Study 24925526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium chloride (TEA; 1 µmol/min)
Number of subjects: 33
Study 24925526 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA, 8 µmol/min)
Number of subjects: 33
Study 24926886 — intervention group
Group type: EXPERIMENTAL
Intervention: OffRoad Re-Entry Catheter System
Number of subjects: 92
Study 24926953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06-0.24 mg/kg/d) administered for 24 months
Number of subjects: 82
Study 24926953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 82
Study 24926953 — intervention group
Group type: COMPARATOR
Intervention: Linear regression in obesity
Number of subjects: 82
Study 24926953 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression in lipodystrophy
Number of subjects: 82
Study 24927802 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person results delivery by a genetic counselor
Number of subjects: 0
Study 24927802 — intervention group
Group type: COMPARATOR
Intervention: Online results delivery through the testing company's website
Number of subjects: 0
Study 24927855 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT™ in PREVAIL JAPAN cohort
Number of subjects: 301
Study 24927855 — intervention group
Group type: COMPARATOR
Intervention: Edwards SAPIEN XT™ in Massy cohort
Number of subjects: 301
Study 24927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2)); administered IV on days 1 and 15 for up to six 28-day cycles.
Number of subjects: 12
Study 24927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab and bendamustine;
Number of subjects: 12
Study 24927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Otlertuzumab in combination with rituximab and bendamustine;
Number of subjects: 12
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: One breakfast consumed
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: Two breakfasts consumed
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more breakfasts consumed
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: No breakfast consumed
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI percentile relationship
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption by grade
Number of subjects: 651
Study 24928474 — intervention group
Group type: EXPERIMENTAL
Intervention: No breakfast among obese youth
Number of subjects: 651
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab + docetaxel (n=15)
Number of subjects: 19
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab + gemcitabine (n=12)
Number of subjects: 19
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab + paclitaxel + carboplatin (n=12)
Number of subjects: 19
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab + PLD (n=14)
Number of subjects: 19
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab (alone)
Number of subjects: 19
Study 24928772 — intervention group
Group type: EXPERIMENTAL
Intervention: carlumab + chemotherapy (all arms)
Number of subjects: 19
Study 24929258 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal progesterone levels (≤4.77 nmol/L or ≤1.5 ng/mL)
Number of subjects: 158
Study 24929258 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated progesterone levels (>4.77 nmol/L or >1.5 ng/mL)
Number of subjects: 158
Study 24929258 — intervention group
Group type: COMPARATOR
Intervention: Elevated progesterone levels (meta-analysis)
Number of subjects: 158
Study 24929484 — intervention group
Group type: COMPARATOR
Intervention: Volatile organic compounds (VOCs) in bile analyzed using selected ion flow tube mass spectrometry (SIFT-MS).
Number of subjects: 96
Study 24929484 — intervention group
Group type: COMPARATOR
Intervention: Predictive model for pancreatic cancer diagnosis based on VOC levels.
Number of subjects: 96
Study 24929893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + weight loss (AEX + WL)
Number of subjects: 33
Study 24929893 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 33
Study 24929893 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 24930123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D volumetric ICE imaging
Number of subjects: 15
Study 24930123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D volumetric ICE imaging with color Doppler
Number of subjects: 15
Study 24930531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 24930597 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively measured energy intake (EI) using doubly labeled water (DLW) assessment
Number of subjects: 253
Study 24930597 — intervention group
Group type: COMPARATOR
Intervention: Self-reported habitual caloric intake based on a food frequency measure
Number of subjects: 253
Study 24930597 — intervention group
Group type: COMPARATOR
Intervention: Baseline resting metabolic rate (RMR)
Number of subjects: 253
Study 24931753 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctium lappa (Lappa) prescribed in potencies from 6c to 1M over 6 months
Number of subjects: 34
Study 24932181 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy
Number of subjects: 328
Study 24932181 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast combined with ICS
Number of subjects: 328
Study 24932181 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast add-on therapy
Number of subjects: 328
Study 24932223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 51
Study 24932223 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 51
Study 24932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CSE
Number of subjects: 174
Study 24932797 — intervention group
Group type: COMPARATOR
Intervention: Normal CSE
Number of subjects: 174
Study 24934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Blast plus impact complex TBI
Number of subjects: 255
Study 24934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blast related TBI
Number of subjects: 255
Study 24934200 — intervention group
Group type: COMPARATOR
Intervention: Blast-exposed controls
Number of subjects: 255
Study 24934200 — intervention group
Group type: COMPARATOR
Intervention: Non-blast-exposed controls
Number of subjects: 255
Study 24934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposure intensity
Number of subjects: 255
Study 24934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 255
Study 24934364 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 70
Study 24934364 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression levels of CK-18, CK-19, and CEA
Number of subjects: 70
Study 24934364 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 24934501 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (mean duration 7.2 months)
Number of subjects: 181
Study 24934501 — intervention group
Group type: COMPARATOR
Intervention: Non-breastfeeding
Number of subjects: 181
Study 24934506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast acetylator genotype in Cohort 1 (type 1 diabetes)
Number of subjects: 9813
Study 24934506 — intervention group
Group type: EXPERIMENTAL
Intervention: Top signal rs4921914 in Cohort 2 (without diabetes)
Number of subjects: 9813
Study 24934506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast acetylator genotype
Number of subjects: 9813
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan procedure
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated brain natriuretic peptide (>21 pg/mL) and low Child Health Questionnaire physical summary score (<44)
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire physical summary score
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire psychosocial summary score
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 physical aggregate score
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 mental aggregate score
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional cardiac surgery
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter intervention
Number of subjects: 546
Study 24934522 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmia requiring treatment
Number of subjects: 546
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dehydration Scale (CDS)
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sodium/potassium ratio
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sodium
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional sodium excretion
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine measurements
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 216
Study 24935348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 216
Study 24936168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity proactive service
Number of subjects: 586
Study 24936168 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity reactive service
Number of subjects: 586
Study 24938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine cue exposure
Number of subjects: 51
Study 24938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Response inhibition cues
Number of subjects: 51
Study 24939214 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg/d
Number of subjects: 28
Study 24939214 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg/d with elevated TSH
Number of subjects: 28
Study 24940525 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 0
Study 24940525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24940526 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (combined Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Number of subjects: 65
Study 24940526 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 65
Study 24940526 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 65
Study 24942210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg every 3 weeks)
Number of subjects: 162
Study 24944232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg plus abacavir/lamivudine (600/300 mg) once daily
Number of subjects: 13
Study 24944546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sodium citrate supplementation (0.5 g kg(-1) administered 120 min pre-trial)
Number of subjects: 10